Which patient parameters will a nurse monitor in a patient receiving foscarnet

Description

Antivirals are agents used to treat the diseases caused by viruses such as warts and common colds.

Table of Common Drugs and Generic Names

Here is a table of commonly encountered antivirals, their generic names, and brand names:

Disease Spotlight: Viral Diseases

• Viruses are composed of a single DNA or RNA inside a protein coat. Viruses must enter a cell in order for them to carry on with their metabolic processes.
• Upon successful entry, viruses inject their DNA or RNA to the cell and the cell is altered in such a manner that it is now “programmed” to control the metabolic processes that the virus needs to survive.
• Because viruses are contained in the cells, researchers find it difficult to develop vaccines. However, viruses respond to some antiviral therapy including influenza A viruses, herpes viruses, CMV, HIV, hepatitis B and C viruses, and some viruses that cause warts and eye infections.

Agents for Influenza A and Respiratory Viruses

• These agents are used to treat the signs and symptoms of respiratory flu caused by influenza A and B viruses as well as respiratory syncytial viruses (RSV). While vaccines are available, drug therapy would be the best option if patients manifest the viral infection and spontaneous resolution does not occur.

The desired and beneficial action of agents for respiratory viruses is:

• Unknown. However, the belief is that these agents prevent shedding of the viral protein coat and entry of the virus into the cell. This prevents replication and therefore causes viral death.

Agents for respiratory viruses are indicated for the following medical conditions:

• Respiratory flu, especially in health care workers and high-risk individuals
• Oseltamivir is the only antiviral agent that has been shown to be effective in treating H1N1 and avian flu.
• Zidovudine has been safely used in pregnant women. 

Here are some important aspects to remember for indication of agents for respiratory viruses in different age groups:

Children

• This age group is very sensitive to the effects of most antivirals and therefore more severe reactions can be expected.
• In addition, many antivirals do not have proven safety and efficacy in children.
• Caution must be applied and smaller doses are given for children.

Adults

• This age group should be educated about the dangers of using antibiotics for viral diseases.
• Emphasis is given on patients with HIV about the limitations of antiviral drugs with regards to the curative aspect of the disease.

Pregnant women

• Generally, pregnant women are not given antivirals unless the benefits clearly outweigh the risks to the fetus or neonate.
• Women of childbearing age should be advised to use barrier contraceptives if they take any of these drugs.
• The Centers for Disease Control and Prevention (CDC) advises that women with HIVinfection should not breast-feed to protect the neonate from the viruses. 

Older adults

• Older patients are more susceptible to adverse effects of antiviral therapy, particularly those with hepatic and renal dysfunctions.

Here are the characteristic interactions of agents for respiratory viruses and the body in terms of absorption, distribution, metabolism, and excretion:

The following are contraindications and cautions for the use of agents for respiratory viruses:

• Renal impairment. Alters metabolism and excretion of drugs, particularly amantadine, zanamivir, and oseltamivir.
• Pregnancy and lactation. Amantadine, rimantadine, and oseltamivir should only be used for treatment if benefits outweigh the risks.

Use of agents for respiratory viruses may result to these adverse effects:

• CNS: adverse effects that may be related to possible effects of dopamine levels in the brain, like light-headedness, dizziness, insomnia
• CV: orthostatic hypotension
• GU: urinary retention

The following are drug-drug interactions involved in the use of agents for respiratory viruses:

• Anticholinergics: increased atropine-like effects with amantadine or rimantadine
• Acetaminophen and aspirin: loss of these drugs’ effectiveness with rimantadine
• Antacids: reduced effectiveness of ribavirin
• NRTIs: reduced effectiveness of ribavirin
• Isoniazid: increased incidence of rifampin-related hepatitis
• Antiarrhythmics, hormonal contraceptives, corticosteroids, antifungals, CNS depressants: decreased effectiveness of these drugs if combined with rifampin
• St. John’s wort: decreased serum levels of protease inhibitors; increased metabolism of antivirals metabolized through cytochrome P450 system

Here are important nursing considerations when administering antiviral agents for influenza A and other respiratory viruses:

These are the important things the nurse should include in conducting assessment, history taking, and examination:

• Assess for the mentioned cautions and contraindications (e.g. drug allergies, hepatorenal impairment, pregnancy and lactation, etc.) to prevent any untoward complications.
• Perform a thorough physical assessment (other medications taken, orientation and reflexes, vital signs, etc.) to establish baseline data before drug therapy begins, to determine effectiveness of therapy, and to evaluate for occurrence of any adverse effects associated with drug therapy.

Here are some of the nursing diagnoses that can be formulated in the use of these drugs for therapy:

• Acute pain related to GI, CNS, or GU effects of the drug
• Disturbed sensory perception (kinesthetics) related to CNS effects of the drug

These are vital nursing interventions done in patients who are taking antiviral agents for respiratory viruses:

• Administer drug as prescribed as soon after exposure to the virus is possible to enhance effectiveness and decrease the risk of complications due to viral infection.
• Administer influenza A vaccine before the flu season begins, if at all possible, to decrease the risk of contracting the flu and decrease the risk of complications.
• Instruct the patient about the appropriate dosage scheduling regimen; safety precautions, including changing position slowly and avoiding driving and hazardous tasks that should be taken if CNS effects occur; the need to report any adverse effects such as difficulty walking or talking to enhance the patient knowledge about drug therapy and to promote compliance.
• Educate client on drug therapy to promote understanding and compliance.

Here are aspects of care that should be evaluated to determine effectiveness of drug therapy:

• Monitor patient response to therapy (prevention of respiratory flu-like symptoms and alleviation of flu-like symptoms).
• Monitor for adverse effects (e.g. changes in orientation and affect, blood pressure, urinary output, liver or renal function test changes, etc).
• Evaluate patient understanding on drug therapy by asking patient to name the drug, its indication, and adverse effects to watch for.
• Monitor patient compliance to drug therapy.

Agents for Herpes and Cytomegaloviruses

• These agents are used to the infections caused by herpes (e.g. cold sores, encephalitis, shingles, and genital infections) and CMV (e.g. infections affecting the eyes, respiratory tract, and liver).

The desired and beneficial action of agents for herpes virus and CMV is:

• Inhibiting viral DNA replication by competing with viral substrates to form shorter, noneffective DNA chains.

Agents for herpes virus and CMV are indicated for the following medical conditions:

• Infections caused by DNA viruses herpes simplex, herpes zoster, and CMV
• Effective in immunocompromised individuals (e.g. patients with AIDS and multiple infections)
• Acyclovir is the drug of choice for children with herpes virus or CMV infections.

Here are the characteristic interactions of agents for herpes virus and CMV and the body in terms of absorption, distribution, metabolism, and excretion:

The following are contraindications and cautions for the use of agents for herpes virus and CMV:

• Known allergy to drug. Prevent hypersensitivity reactions
• Renal impairment. Alter drug excretion
• Pregnancy and lactation. Prevent adverse effects to fetus or neonate
• Severe CNS disorders. Drugs can cause headache, neuropathy, paresthesias, confusion, and hallucinations
• Children with AIDS. Cidofovir has potential carcinogenic effects and effects on fertility. Caution must be applied.
• Children. Foscarnet, ganciclovir, and valganciclovir can affect bone development and growth. Also, safety of use in children younger than 18 years has not been established for famciclovir.

Use of agents for herpes virus and CMV may result to these adverse effects:

• CNS: headache, depression, paresthesias, neuropathy
• GI: nausea, vomiting
• GU: renal dysfunction and failure
• IV and topical site: rash, inflammation, burning sensation
• Cidofovir is associated with severe renal toxicity and granulocytopenia.
• Ganciclovir and valganciclovir are associated with bone marrow suppression.
• Foscarnet has been associated with seizures, especially in patients with electrolyte imbalance.

The following are drug-drug interactions involved in the use of agents for herpesvirus and CMV:

• Aminoglycosides: increased renal toxicity
• Zidovudine: increased risk of drowsiness

Here are important nursing considerations when administering antiviral agents for herpesvirus and CMV:

These are the important things the nurse should include in conducting assessment, history taking, and examination:

• Assess for the mentioned cautions and contraindications (e.g. drug allergies, hepatorenal impairment, pregnancy and lactation, severe CNS disorders, etc.) to prevent any untoward complications.
• Perform a thorough physical assessment (other medications taken, orientation and reflexes, skin color, temperature, and lesions, etc.) to establish baseline data before drug therapy begins, to determine effectiveness of therapy, and to evaluate for occurrence of any adverse effects associated with drug therapy.
• Evaluate renal function tests to determine baseline function of the kidneys and to assess adverse effects on the kidney and need to adjust the dose of the drug.

Here are some of the nursing diagnoses that can be formulated in the use of these drugs for therapy:

• Acute pain related to GI, CNS, or local effects of the drug
• Disturbed sensory perception (kinesthetics) related to CNS effects of the drug

These are vital nursing interventions done in patients who are taking antiviral agents for respiratory viruses:

• Administer drug as prescribed as soon after exposure to the virus is possible to enhance effectiveness and decrease the risk of complications due to viral infection.
• Ensure good hydration to decrease the toxic effects on the kidneys.
• Ensure patient takes the complete course of the drug regimen to improve effectiveness and decrease the risk of emergence of resistant viruses.
• Wear protective gloves when applying the drug topically to decrease the risk of exposure to the drug and inadvertent absorption.
• Provide safety precautions (e.g. use of side rails, appropriate lighting, orientation, assistance) if CNS effects occur to protect the patient from injury.
• Monitor renal function tests periodically during treatment to ensure prompt detection and early intervention should renal toxicity develop.
• Educate client on drug therapy to promote understanding and compliance.
• Provide the following patient teaching:
  • Avoid sexual intercourse if genital herpes is being treated because these drugs do not cure the disease.
  • Wear protective gloves when applying topical agents.
  • Avoid driving and hazardous tasks if dizziness or drowsiness occurs.

Here are aspects of care that should be evaluated to determine effectiveness of drug therapy:

• Monitor patient response to therapy (alleviation of signs and symptoms of herpes or CMV).
• Monitor for adverse effects (e.g. orientation and affect, GI upset and renal function).
• Evaluate patient understanding on drug therapy by asking patient to name the drug, its indication, and adverse effects to watch for.
• Monitor patient compliance to drug therapy.

Agents for HIV and AIDS (Antiretroviral Drugs)

Nonnucleoside Reverse Transcriptase Inhibitors

• This antiretroviral drug has direct effects on HIV activities within the cell.

The desired and beneficial action of this antiretroviral drug is:

• Binding directly to HIV reverse transcriptase to block both RNA- and DNA-dependent DNA polymerase activities. They prevent the transfer of information that would allow the virus to carry on the formation of viral DNA. Consequently, replication becomes impossible.

Nonnuceloside reverse transcriptase inhibitors are indicated for the following medical conditions:

• Treatment of patients with documented AIDS or ARC who have decreased numbers of helper T cells and evidence of increased opportunistic infections in combination with other antiviral drugs.

Here are the characteristic interactions of nonnucleoside reverse transcriptase inhibitors and the body in terms of absorption, distribution, metabolism, and excretion:

The following are contraindications and cautions for the use of nonnucleoside reverse transcriptase inhibitors:

• Pregnancy. No adequate studies of nonnucleoside reverse transcriptase inhibitors so use should be limited only in which benefits clearly outweigh any risks.
• Children. Safety for the use of delavirdine is not established.

Use of nonnucleoside reverse transcriptase inhibitors may result to these adverse effects:

• CNS: dizziness, blurred vision, headache
• GI: dry mouth, constipation or diarrhea, nausea, abdominal pain, dyspepsia
• Flu-like syndrome may occur but this may also be because of the underlying disease.

The following are drug-drug interactions involved in the use of nonnucleoside reverse transcriptase inhibitors:

• Delavirdine should not be combined with antiarrhythmics, clarithromycin, dapsone, antituberculosis drugs, calcium-channel blockers, warfarin, quinidine, indinavir, saquinavir, or dapsone.
• Efavirenz should not be combined with midazolam, rifabutin, triazolam, or ergot derivatives.
• Hormonal contraceptives and protease inhibitors: lack of effectiveness of nevirapine
• St. John’s wort: decreased antiviral effects

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

• This antiretroviral drug was the first class of drug developed to treat HIV infections. This competes with the naturally occurring nucleosides within a human cell that the virus would need to develop.

The desired and beneficial action of this antiretroviral drug is:

• Competing with the naturally occurring nucleosides within the cell that the virus would use to build DNA chain. These nucleosides, however, lack a substance needed to extend the DNA chain. Consequently, chain cannot lengthen and insert itself into the host DNA.

NRTIs are indicated for the following medical conditions:

• Combination therapy for the treatment of adults and children with HIV
• Lamivudine as an oral solution can be used in treatment of chronic hepatitis B
• Zidovudine is used in prevention of maternal transmission of HIV.

Here are the characteristic interactions of nonnucleoside NRTIs and the body in terms of absorption, distribution, metabolism, and excretion:

The following are contraindications and cautions for the use of NRTIs:

• Pregnancy. No adequate studies of NRTIs so use should be limited, except for zidovudine, which has been proven to be safe.
• Hepatic dysfunction, severe renal impairment. Caution with use of tenofovir, zidovudine, and emtricitabine.
• Bone marrow suppression. Can be aggravated by zidovudine.

Use of NRTIs may result to these adverse effects:

• Abacavir: serious-to-fatal hypersensitivity reactions (fever, chills, rash, fatigue, GI upset, flu-like symptoms) can occur and drug must be discontinued immediately and listed with the Abacavir Hypersensitivity Registry
• Didanosine: serious pancreatitis, hepatomegaly, and neurological problems
• Emtricitabine, tenofovir: severe and fatal hepatomegaly with steatosis
• Zidovudine: severe bone marrow suppression
• Tenofovir: changes in body fat distribution, with loss of fat from arms, legs, and face and deposition of fat on the trunk, neck, and face.

The following are drug-drug interactions involved in the use of NRTIs:

• Tenofovir: increase serum level of didanosine; if in combine therapy, administer 2 hours before or 1 hour after didanosine was given
• Alcohol: severe toxicity with abacavir
• Antibiotics, antifungals: decreased effectiveness of these drugs if combined with didanosine
• Cyclosporine: severe drowsiness and lethargy if combined with zidovudine
• Lamivudine and zalcitabine inhibit the effects of each other.

Protease Inhibitors

• Protease inhibitors block protease activity within the HIV virus.

The desired and beneficial action of this antiretroviral drug is:

• Rendering the virus immature and noninfective by blocking protease which is essential for the maturation of an infectious virus.
• As a result, the virus is unable to fuse with and inject itself into a cell.

Protease inhibitors are indicated for the following medical conditions:

• Combination therapy for the treatment of HIV infections.

Here are the characteristic interactions of nonnucleoside NRTIs and the body in terms of absorption, distribution, metabolism, and excretion:

The following are contraindications and cautions for the use of protease inhibitors:

• Pregnancy, lactation. Only saquinavir is not teratogenic. However, it can cross into breast milk.
• Hepatic dysfunction. Increased toxicity especially with fosamprenavir and darunavir
• Patients taking antidiabetic drugs. Darunavir can cause diabetes mellitus and/or hyperglycemia; dose adjustment is required.
• Darunavir is associated with mild to severe dermatologic reactions including Steven Johnson syndrome.
• Safety of indinavir for use in children younger than 12 years has not been established.
• Darunavir should not be used in children younger than 3 years of age because of the potential for toxic effects.

Use of protease inhibitors may result to these adverse effects:

• GI: nausea, vomiting, diarrhea, anorexia, changes in liver function (elevated cholesterol and triglyceride)
• Skin: rashes, pruritus, Steven Johnson syndrome

The following are drug-drug interactions involved in the use of protease inhibitors:

• Pimozide, rifampin, triazolam, midazolam: severe toxic effects with nelfinavir
• Nonsedating antihistamines, sedatives/hypnotics, antiarrhythmics: many potentially serious toxic effects with ritonavir

Fusion Inhibitor

• This antiretroviral drug was introduced in 2003.
• Acts on different site than do other HIV antivirals.

The desired and beneficial action of this antiretroviral drug is:

• Preventing the fusion of the virus with the human cellular membrane, thereby preventing entry of HIV-1 virus into the cell.

Fusion inhibitors are indicated for the following medical conditions:

• Combination therapy for the treatment of adults and children older than 6 years who have evidence of HIV-1 replication despite ongoing antiretroviral therapy.

Here are the characteristic interactions of fusion inhibitors and the body in terms of absorption, distribution, metabolism, and excretion:

The following are contraindications and cautions for the use of fusion inhibitors:

• Pregnancy and lactation. Potential adverse effects to the fetus and neonate.
• Known hypersensitivity to the drug.

Use of fusion inhibitors may result to these adverse effects:

• CNS: insomnia, depression, peripheral neuropathy
• GI: nausea, diarrhea
• Respiratory: pneumonia
• Local: injection-site reactions

• No reported drug interactions, but caution should be used when it is combined with any drug.

CCR5 Coreceptor Antagonist

• This antiretroviral drug was introduced in 2007.

The desired and beneficial action of this antiretroviral drug is:

• Blocking the receptor site on the cell membrane to which the HIV virus needs to interact to enter the cell.

CCR5 coreceptor antagonists are indicated for:

• Combination therapy with other antivirals.

Here are the characteristic interactions of CCR5 coreceptor antagonists and the body in terms of absorption, distribution, metabolism, and excretion:

The following are contraindications and cautions for the use of CCR5 coreceptor antagonists:

• Pregnancy, lactation, known hypersensitivity to drugs.
• Renal impairment. Increased risk of toxicity.
• Safety of use for children not established.

Use of CCR5 coreceptor antagonists may result to these adverse effects:

• CNS: dizziness, changes in consciousness
• Severe hepatotoxicity has been reported with maraviroc, often preceded with systemic allergic reaction with eosinophilia and rash.

The following are drug-drug interactions involved in the use of CCR5 coreceptor antagonists:

• Cyctochrome P450 CYP3A inhibitors (ketoconazole, lopinavir/ritonavir, saquinavir, ritonavir, atazanavir, delavirdine): risk of increased serum levels and toxicity of maraviroc.
• CYP3A inducers (nevirapine, rifampin, efavirenz: decreased serum levels and loss of effectiveness of maraviroc
• St. John’s wort: loss of antiviral effect of maraviroc

Integrase Inhibitors

• This antiretroviral drug was released in late 2007.

The desired and beneficial action of this antiretroviral drug is:

• Inhibiting the activity of the virus-specific enzyme integrase, an encoded enzyme needed for replication. Blocking integrase prevents the formation of HIV-1 provirus leading to decreased viral load and increased active CD4 cells.

Integrase inhibitors are indicated for:

• Reserved for use in patients who have been treated with other antivirals and have evidence of a return to viral replication.

Here are the characteristic interactions of integrase inhibitors and the body in terms of absorption, distribution, metabolism, and excretion:

The following are contraindications and cautions for the use of integrase inhibitors:

• It is contraindicated with known hypersensitivity to any component of the drug, as initial treatment for adults, for use in children, and for nursing mothers.
• Caution should be used if the patient is at risk for rhabdomyolysis or myopathy and during pregnancy.

Use of integrase inhibitors may result to these adverse effects:

• CNS: headache, dizziness
• Musculoskeletal: rhabdomyolysis, myopathy

The following are drug-drug interactions involved in the use of integrase inhibitors:

• Rifampin: decreased serum levels of raltegravir
• St. John’s wort: reduced effectiveness of antiviral

Nursing Considerations for Antiretroviral Drugs

Here are important nursing considerations when administering antiretroviral drugs:

These are the important things the nurse should include in conducting assessment, history taking, and examination:

• Assess for the mentioned cautions and contraindications (e.g. drug allergies, hepatorenal impairment, pregnancy and lactation, etc.) to prevent any untoward complications.
• Perform a thorough physical assessment (other medications taken, orientation and reflexes, vital signs, skin color, temperature, and lesions, etc.) to establish baseline data before drug therapy begins, to determine effectiveness of therapy, and to evaluate for occurrence of any adverse effects associated with drug therapy.
• Evaluate hepatic and renal function tests to determine baseline function of the kidneys and liver.
• Check results of CBC with differential to monitor bone marrow activity and helper T cell number to determine the severity of the disease and indicate the effectiveness of the drugs.

Here are some of the nursing diagnoses that can be formulated in the use of these drugs for therapy:

• Acute pain related to GI, CNS, or dermatological effects of the drug
• Disturbed sensory perception (kinesthetics) related to CNS effects of the drug
• Imbalanced nutrition: less than body requirements related to GI effects of the drug

These are vital nursing interventions done in patients who are taking antiretroviral drugs:

• Monitor renal and hepatic function before and during therapy to detect changes requiring dose adjustments or additional treatment as needed.
• Ensure patient takes the complete course of the drug regimen and takes all drugs included in a particular combination to improve the effectiveness of the drug and decrease the risk of emergency of resistant viral strains.
• Administer the drug round the clock, if indicated, to provide the critical concentration needed for the drug to be effective.
• Stop drug if sever rash occurs, especially if accompanied by blisters, fever, and other signs, to avert potentially serious reactions.
• Provide safety precautions (e.g. use of side rails, appropriate lighting, orientation, assistance) If CNS effects occur, to protect patient from injury.
• Educate client on drug therapy to promote understanding and compliance.

Here are aspects of care that should be evaluated to determine effectiveness of drug therapy:

• Monitor patient response to therapy (alleviation or reduction of signs and symptoms of AIDS or ARC and maintenance of helper T cell levels).
• Monitor for adverse effects (e.g. changes in orientation and affect, GI upset, renal and hepatic function, skin, levels of blood components, etc).
• Evaluate patient understanding on drug therapy by asking patient to name the drug, its indication, and adverse effects to watch for.
• Monitor patient compliance to drug therapy.

Anti-Hepatitis B and C Agents

• Hepatitis B is a serious-to-potentially fatal viral infection of the liver. It can be spread by blood or blood products, sexual contact, or contaminated needles or instruments. Individuals affected may develop a chronic condition or become a carrier.
• Hepatitis C is the leading cause of most liver transplants due to progressive liver disease. After initial infection with HCV, most people develop chronic hepatitis C while some will develop cirrhosis of the liver. Mode of transmission is similar with HBV.

The desired and beneficial action of this anti-hepatitis drug is:

• Anti-hepatitis B agents inhibit reverse transcriptase in hepatitis B virus and cause DNA chain termination, leading to blocked viral replication and decreased viral load.

Anti-hepatitis agents are indicated for:

• Treatment of adults with chronic hepatitis B and C who have evidence of active viral replication and either evidence of persistent elevations in serum aminotransferase or histologically active disease.

Here are the characteristic interactions of anti-hepatitis agents and the body in terms of absorption, distribution, metabolism, and excretion:

The following are contraindications and cautions for the use of anti-hepatitis agents:

• Anti-hepatitis B: known allergy to drugs, to prevent hypersensitivity reactions; lactation, to prevent potential toxicity to the infant; renal and liver impairment, because of increased risk of toxicity.
• Anti-hepatitis C: pregnancy, hepatitis B, and HIV infections, as safety is not established.

Use of anti-hepatitis agents may result to these adverse effects:

• Anti-hepatitis B: should not be stopped immediately because of potential risk of hepatitis B exacerbation

• CNS: headache, dizziness, nausea
• GI: diarrhea, elevated liver enzymes, severe hepatomegaly with steatosis
• GU: lactic acidosis and renal impairment

• Anti-hepatitis C
  • CNS: headache, fatigue
  • GI: nausea, diarrhea
  • Immunological: bone marrow suppression, severe skin reactions

The following are drug-drug interactions involved in the use of anti-hepatitis agents:

• Nephrotoxic drugs: increased risk of renal toxicity

Nursing Considerations

Here are important nursing considerations when administering anti-hepatitis drugs:

These are the important things the nurse should include in conducting assessment, history taking, and examination:

• Assess for the mentioned cautions and contraindications (e.g. drug allergies, hepatorenal impairment, pregnancy and lactation, etc.) to prevent any untoward complications.
• Perform a thorough physical assessment (other medications taken, orientation and reflexes, vital signs, etc.) to establish baseline data before drug therapy begins, to determine effectiveness of therapy, and to evaluate for occurrence of any adverse effects associated with drug therapy.
• Evaluate hepatic and renal function tests to determine baseline function of the kidneys and liver.

Here are some of the nursing diagnoses that can be formulated in the use of these drugs for therapy:

• Acute pain related to GI and CNS effects of the drug
• Imbalanced nutrition: less than body requirements related to GI effects of the drug

These are vital nursing interventions done in patients who are taking anti-hepatitis drugs:

• Monitor renal and hepatic function before and during therapy to detect changes requiring dose adjustments or additional treatment as needed.
• Withdraw the drug and monitor the patient if he or she develops signs of lactic acidosis or hepatotoxicity because these adverse effects can be life threatening.
• Caution patient to not run out of this drug but to take it continually because acute exacerbation of hepatitis B can occur when the drug is stopped.
• Advise patients that these drugs do not cure the disease and there is still a risk of transferring the disease, so the patient should continue to take appropriate steps to prevent transmission of hepatitis B.
• Provide the following patient teachings:
  • Have regular blood tests and medical follow-up.
  • Realize that GI upset, with nausea and diarhea, is common with this drug.
  • Report severe weakness, muscle pain, palpitations, yellowing of the eyes or skin, and trouble breathing.
• Educate client on drug therapy to promote understanding and compliance.

Here are aspects of care that should be evaluated to determine effectiveness of drug therapy:

• Monitor patient response to therapy (decreased viral load).
• Monitor for adverse effects (e.g. liver or renal dysfunction, headache, nausea, diarrhea, etc).
• Evaluate patient understanding on drug therapy by asking patient to name the drug, its indication, and adverse effects to watch for.
• Monitor patient compliance to drug therapy.

Pharmacology: Antiviral Drugs (PM)*

Choose the letter of the correct answer. Good luck!

Congratulations - you have completed Pharmacology: Antiviral Drugs (PM)*. You scored %%SCORE%% out of %%TOTAL%%. Your performance has been rated as %%RATING%%

Your answers are highlighted below.

Shaded items are complete.

For which symptoms will the nurse monitor in a patient suspected of developing digoxin toxicity?

Which patient assessment findings would the nurse associate with potential digoxin toxicity?

Which answer would the nurse provide if asked how phenytoin works to control seizure?

Which action of allopurinol would the nurse include in teaching a patient newly diagnosed with gout?